Mynvax
4 known investors
Mynvax develops engineered protein subunit vaccines using a protein stabilization platform, including influenza vaccine candidates based on stabilized hemagglutinin regions and thermo-tolerant vaccines against SARS-CoV-2 variants. Incubated at the Indian Institute of Science, the biotech startup collaborates with research labs, CDMOs, and vaccine manufacturers, with some programs funded by Indian government agencies.